<DOC>
	<DOC>NCT02252198</DOC>
	<brief_summary>Assess sensitivity and specificity of two nucleic acid amplification tests, namely Epistem Genedrive® and MolbioTruenat™ in raw sputum compared to the WHO-endorsed GeneXpert® MTB/RIF assay using a gold standard of four cultures</brief_summary>
	<brief_title>Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests</brief_title>
	<detailed_description>- Estimate the accuracy of the Epistem Genedrive® and MolbioTruenat™ in raw sputum and in sputum pellets. - Assess the operational feasibility of Epistem Genedrive® and MolbioTruenat™ - Determine and compare costs between the Epistem Genedrive®, MolbioTruenat™, and Xpert MTB/RIF tests</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>• Clinical suspicion of pulmonary TB (including cough ≥2 weeks and at least 1 other symptom typical of TB); Age 18 years or above; Willingness to have a study followup visit, if necessary, approximately two months after enrollment Willingness to provide 3 sputum specimens at enrollment Provision of informed consent. • Receipt of ≥48 cumulative hours OR three or more doses of antiTB treatment (defined as combination antiTB therapy intended to treat active TB) within 60 days prior to completion of sputum collection; Inability to provide informed consent (e.g. mentally impaired) Enrolled individuals who do not provide a first sputum sample of ≥ 2ml and a second and third sputum sample of ≥ 1ml each will be classified as early exclusions.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>